[Obtaining a productive strain of Streptoverticillium griseocarneum var. bleomycini that yields the new antineoplastic antibiotic, bleomycetin].
Selection of the organism producing bleomycin, a multicomponent antitumor antibiotic, was performed. The aim was the selection of a more active strain with preferable synthesis of component A5 (bleomycetin) of the bleomycin complex. Optimal variants of the conditions for mutagensis with UV light and gamma-rays in step-wise selection of the active strain were determined and a possibility of selecting analog-resistant mutants with the use of structural analogs of the metabolites participating in synthesis of the bleomycin molecule was studied. A mutant analog-resistant strain capable of supersynthesis of bleomycin A5 (bleomycetin) was selected, the biosynthetic capacity of Streptoverticillum griseocarneum var. bleomycini being increased at least 19 times.